Literature DB >> 17725429

Molecular and genotypic characterization of human thyroid follicular cell carcinoma-derived cell lines.

Ana Margarida Meireles1, Ana Preto, Ana Sofia Rocha, Ana Paula Rebocho, Valdemar Máximo, Isabel Pereira-Castro, Severina Moreira, Tália Feijão, Tiago Botelho, Ricardo Marques, Vítor Trovisco, Luís Cirnes, Cíntia Alves, Sérgia Velho, Paula Soares, Manuel Sobrinho-Simões.   

Abstract

OBJECTIVE: Our aim was to characterize the molecular and genotypic profile of eight thyroid carcinoma-derived cell lines-TPC1, FB2, B-CPAP, K1, XTC-1, C643, 8505C, and Hth74-in order to use them as in vitro models of thyroid carcinogenesis.
DESIGN: We evaluated the expression of five thyroid-specific genes (Tg, TSHr, TPO, PAX8, and TTF-1) to establish the cell lineage and to assess the differentiation status of each of the cell lines. We screened for mutations in the most relevant oncogenes/tumor suppressor genes affected in thyroid carcinogenesis: RAS, BRAF, CTNNB1, and TP53 along with RET/PTC rearrangements. Considering the putative relevance in general carcinogenesis, we have also studied other molecules such as EGFR, PI3K, RAF-1, and THRB. To determine the genetic identity of the cell lines, we performed genotypic analysis. MAIN OUTCOME: The panel of cell lines we have studied displayed activation of several oncogenes (BRAF, RAS, RET/PTC) and inactivation of tumor suppressor genes (TP53) known to be important for thyroid carcinogenesis. Two of the cell lines-TPC1 and FB2-shared the same genotypic profile, probably representing clones of an ancestor cell line (TPC1).
CONCLUSION: Due to their different molecular alterations, these cell lines represent a valuable tool to study the molecular mechanisms underlying thyroid carcinogenesis. We suggest that genotypic analyses should be included as a routine procedure to guarantee the uniqueness of each cell line used in research.

Entities:  

Mesh:

Year:  2007        PMID: 17725429     DOI: 10.1089/thy.2007.0097

Source DB:  PubMed          Journal:  Thyroid        ISSN: 1050-7256            Impact factor:   6.568


  35 in total

1.  Quantitative high-throughput drug screening identifies novel classes of drugs with anticancer activity in thyroid cancer cells: opportunities for repurposing.

Authors:  Lisa Zhang; Mei He; Yaqin Zhang; Naris Nilubol; Min Shen; Electron Kebebew
Journal:  J Clin Endocrinol Metab       Date:  2011-12-14       Impact factor: 5.958

2.  "Thyroid cancer" cell line misidentification: a time for proactive change.

Authors:  Matthew D Ringel
Journal:  J Clin Endocrinol Metab       Date:  2008-11       Impact factor: 5.958

3.  Cyclic AMP inhibits the proliferation of thyroid carcinoma cell lines through regulation of CDK4 phosphorylation.

Authors:  Ana Sofia Rocha; Sabine Paternot; Katia Coulonval; Jacques E Dumont; Paula Soares; Pierre P Roger
Journal:  Mol Biol Cell       Date:  2008-09-17       Impact factor: 4.138

4.  Involvement of p53 in cell death following cell cycle arrest and mitotic catastrophe induced by rotenone.

Authors:  António Pedro Gonçalves; Valdemar Máximo; Jorge Lima; Keshav K Singh; Paula Soares; Arnaldo Videira
Journal:  Biochim Biophys Acta       Date:  2011-01-09

5.  Late intervention with anti-BRAF(V600E) therapy induces tumor regression in an orthotopic mouse model of human anaplastic thyroid cancer.

Authors:  Matthew A Nehs; Carmelo Nucera; Sushruta S Nagarkatti; Peter M Sadow; Dieter Morales-Garcia; Richard A Hodin; Sareh Parangi
Journal:  Endocrinology       Date:  2011-12-27       Impact factor: 4.736

6.  Thyroid cancer resistance to vitamin D receptor activation is associated with 24-hydroxylase levels but not the ff FokI polymorphism.

Authors:  Vibha Sharma; Deborah Fretwell; Zachary Crees; Anna Kerege; Joshua P Klopper
Journal:  Thyroid       Date:  2010-10       Impact factor: 6.568

Review 7.  Potential utility and limitations of thyroid cancer cell lines as models for studying thyroid cancer.

Authors:  Tania Pilli; Kanteti V Prasad; Shankar Jayarama; Furio Pacini; Bellur S Prabhakar
Journal:  Thyroid       Date:  2009-12       Impact factor: 6.568

8.  A novel orthotopic mouse model of human anaplastic thyroid carcinoma.

Authors:  Carmelo Nucera; Matthew A Nehs; Michal Mekel; Xuefeng Zhang; Richard Hodin; Jack Lawler; Vânia Nose; Sareh Parangi
Journal:  Thyroid       Date:  2009-10       Impact factor: 6.568

9.  Antisense-miR-21 enhances differentiation/apoptosis and reduces cancer stemness state on anaplastic thyroid cancer.

Authors:  Vahid Haghpanah; Parviz Fallah; Rezvan Tavakoli; Mahmood Naderi; Hilda Samimi; Masoud Soleimani; Bagher Larijani
Journal:  Tumour Biol       Date:  2015-08-20

10.  Proliferation and survival molecules implicated in the inhibition of BRAF pathway in thyroid cancer cells harbouring different genetic mutations.

Authors:  Ana Preto; Joana Gonçalves; Ana P Rebocho; Joana Figueiredo; Ana M Meireles; Ana S Rocha; Helena M Vasconcelos; Hugo Seca; Raquel Seruca; Paula Soares; Manuel Sobrinho-Simões
Journal:  BMC Cancer       Date:  2009-10-31       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.